Metvix PDT is now available at Odette Cancer Centre as an additional treatment option for patients NMSc

Metvix PDT is now available at Odette Cancer Centre as an additional treatment option for patients NMSc -

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in collaboration with Galderma Canada are announcing that Metvix PDT (photodynamic therapy), is now available at Odette cancer Centre in Toronto as an additional treatment option for patients with NMSC (nonmelanoma skin cancer). For eligible patients the positive impact of Metvix PDT can not be overestimated in precancerous AK (actinic keratoses) and superficial BCC (basal cell carcinoma) treatment.

treatment

Metvix PDT delivers precisely targeted for AK and BCC. Metvix PDT is changing the treatment of AK and BCC patients by offering preferred advantages:

• The clinical results comparable to current standard modes of treatment
• procedure minimally non -invasive with superior cosmetic results
• healing can take place in as little as 7-10 days treatment is directed precisely

the Odette Cancer Centre, one of best cancer centers in the world, always offering the highest level of patient care while conducting research and world-class education in a clinical setting. Always committed to improving treatment and patient care, Odette Cancer Centre leads once again the way in providing Metvix PDT for NMSC. Instrumental to bring Metvix PDT Centre Dr. Gregory Czarnota, principal investigator and Director, Program on the Odette Cancer, Dr. Steven Babic, medical physicist, and Dr. Toni Barnes, radiation oncologist are at the forefront of this initiative marks a new area of ​​treatment Conservatory.

the Odette Cancer Centre is a 2 ^e the largest center of fight against cancer in Canada and the 6 ^e the largest center of fight against cancer in North America, ranked among a select group of world-class institutions that engage in intense research, community outreach and provide the full range of patient care.

partnership Galderma and Odette Cancer Centre reinforces the strong commitment of both parties to continue to provide the most innovative and technologically advanced treatments to improve the experience and outcomes of patients when treated for AK and Conservatory.